主要文書

すべての文書を表示

579000

Tamoxifen Citrate

Name: Tamoxifen Citrate
Brand: MM

≥99% (HPLC), Estrogen receptor modulator, powder

別名:

Tamoxifen Citrate, Estrogen Receptor Signaling Regulator I

ログインで組織・契約価格をご覧ください。

サイズを選択してください

表示を変更する

この商品について

実験式（ヒル表記法）:

C₂₆H₂₉NO · xC₆H₈O₇

CAS番号:

54965-24-1

分子量:

371.51 (salt-free basis)

UNSPSC Code:

12352200

NACRES:

NA.77

MDL number:

MFCD00058321

Assay:

≥99% (HPLC)

Form:

powder

Storage condition:

OK to freeze

テクニカルサービス

お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。

お手伝いします

特性

製品名

Tamoxifen Citrate, Tamoxifen is a potent synthetic anti-estrogenic agent.

description

Merck USA index - 14, 9048

Quality Segment

100

assay

≥99% (HPLC)

form

powder

manufacturer/tradename

Calbiochem^®

storage condition

OK to freeze

color

white to off-white

solubility

ethanol: 5 mg/mL, methanol: 5 mg/mL, water: sparingly soluble

shipped in

ambient

storage temp.

2-8°C

SMILES string

N(CCOc1ccc(cc1)\C(=C(\CC)/c3ccccc3)\c2ccccc2)(C)C.[O-]C(=O)C(O)(CC(=O)[O-])CC(=O)[O-].[H+].[H+].[H+]

InChI

1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;

InChI key

FQZYTYWMLGAPFJ-OQKDUQJOSA-N

詳細

General description

A potent synthetic anti-estrogen. A cell-permeable and reversible inhibitor of protein kinase C (IC₅₀ = 10 µM). Induces apoptosis in human malignant glioma cell lines.

A potent synthetic anti-estrogenic agent. A cell-permeable and reversible inhibitor of protein kinase C (IC₅₀ = 10 µM). Induces apoptosis in human malignant glioma cell lines and inhibits prostate cancer cell growth by induction of p21 protein.

Biochem/physiol Actions

Cell permeable: yes

Primary Target
PKC

Product does not compete with ATP.

Reversible: yes

Target IC₅₀: 10 µM against protein kinase C

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Rohlff, C., et al. 1998. Prostate 37, 51.
Couldwell, W.J., et al. 1994. FEBS Lett.345, 43.
Baltuch, G.H., et al. 1993. Neurosurgery33, 495.
Powis, G. 1991. Trends Pharmacol. Sci.12, 188.
Issandou, M., et al. 1990. Cancer Res.50, 5845.
O’Brian, C.A., et al. 1985. Cancer Res.45, 2462.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Harmful & Carcinogenic / Teratogenic (E)

pictograms

GHS08,GHS07,GHS09

signalword

Danger

hcodes

H302,H350,H360D,H410

pcodes

P202 - P264 - P273 - P280 - P301 + P312 - P308 + P313

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1B - Repr. 1B

保管分類

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c